- Poster presentation
- Open Access
Somatostatin receptor scintigraphy in sarcoidosis
© Kamphuis et al; licensee BioMed Central Ltd. 2011
- Published: 23 November 2011
- Angiotensin Converting Enzyme
- Lung Biopsy
- High Serum Level
- Sensitive Imaging
Sarcoidosis is a multisystem granulomatous disorder, most frequently involving the lungs, skin or eyes. Somatostatin receptor scintigraphy (SRS) can localize granulomas by binding to somatostatin receptors that are expressed in sarcoidosis. We studied the patterns of uptake on SRS and correlated them to other disease parameters.
218 patients were studied. The degree of intensity of uptake and localization of sarcoidosis associated lesion (SAL) were determined. The degree of intensity was compared with serum angiotensin converting enzyme (ACE) and serum soluble interleukin-2 receptor (sIL-2R). Elevated levels of serum ACE and sIL-2R have been shown to be associated with active sarcoidosis. Typical patterns on SRS were compared to conventional chest CT-scans and x-rays.
SRS was negative in 28 patients, 10 patients had one -and 180 patients had more SALs. The degree of intensity correlated significantly with higher serum levels of ACE (p = 0.001) and serum levels of sIL-2R (p <0.0001). An elevated level of serum ACE and sIL-2R shows a sensitivity of respectively 96% and 93% for uptake on the SRS. Mediastinal lesions together with either eye, salivary glands, clavicular or hilar localizations on SRS demonstrated a significant characteristic pattern. All patients with abnormal conventional tests had SRS uptake. Moreover, of 94 patients with normal radiological findings 49 expressed pathological SRS uptake. In 36 of these 49 patients a lung biopsy was taken, which revealed sarcoidosis in 31.
The degree of intensity in SRS correlates with sarcoidosis activity (ACE and sIL-2R). SRS is more sensitive in diagnosing sarcoidosis, even in patients with normal chest radiology. SRS therefore provides a useful and sensitive imaging technique to monitor organ involvement and therapy in patients with sarcoidosis.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.